How should hyperglycemia be evaluated and managed in a patient with type 2 diabetes presenting with blood glucose ≥250 mg/dL (or hyperglycemic symptoms) and also for fasting glucose 100–125 mg/dL or random glucose 140–250 mg/dL?

Evaluation and Management of Hyperglycemia in Type 2 Diabetes

Immediate Assessment and Risk Stratification

For blood glucose ≥250 mg/dL with symptoms, check urine or blood ketones immediately to rule out diabetic ketoacidosis, especially if accompanied by nausea, vomiting, abdominal pain, or altered mental status. 1

Critical Glucose Thresholds Requiring Urgent Action

• Blood glucose ≥300 mg/dL: Evaluate for diabetic ketoacidosis or hyperosmolar hyperglycemic state; if ketones are present (≥0.5 mmol/L blood or ≥trace urine), treat as early ketoacidosis and summon physician immediately. 1, 2
• Blood glucose 250–299 mg/dL: Initiate or intensify insulin therapy within 24 hours; this level indicates therapeutic failure requiring immediate intervention. 1, 2
• Fasting glucose 100–125 mg/dL (prediabetes range): Implement lifestyle modifications with 3–6 month trial before pharmacotherapy if HbA1c <7.5%; if HbA1c ≥7.5%, start metformin immediately. 1
• Random glucose 140–250 mg/dL: Start or adjust oral agents; if fasting glucose persistently ≥180 mg/dL despite oral therapy, initiate basal insulin. 1

---

Management Algorithm by Glucose Level

For Blood Glucose ≥250 mg/dL (Severe Hyperglycemia)

Insulin therapy is mandatory and should be initiated immediately; this is the most effective agent when glucose is markedly elevated. 1, 2

Initial Insulin Regimen

• Start basal-bolus insulin immediately if HbA1c ≥10–12% with symptomatic or catabolic features, or if blood glucose ≥300–350 mg/dL. 1, 2
• Total daily dose: 0.3–0.5 units/kg/day, split 50% basal insulin (glargine, detemir, or degludec once daily) and 50% prandial insulin (lispro, aspart, or glulisine divided among three meals). 1, 2
• Example for 70 kg patient: Total 21–35 units/day → 11–18 units basal once daily + 4–6 units before each meal. 2

Aggressive Titration Protocol

• Basal insulin: Increase by 4 units every 3 days if fasting glucose ≥180 mg/dL; increase by 2 units every 3 days if fasting glucose 140–179 mg/dL. 1, 2
• Target fasting glucose: 80–130 mg/dL. 1, 2
• Prandial insulin: Increase each meal dose by 1–2 units (10–15%) every 3 days based on 2-hour postprandial glucose. 2
• Target postprandial glucose: <180 mg/dL. 1, 2

Foundation Therapy

• Continue metformin at maximum tolerated dose (up to 2,000–2,550 mg/day) unless contraindicated; this reduces total insulin requirements by 20–30% and provides superior glycemic control. 1, 2
• Discontinue sulfonylureas when starting basal-bolus insulin to prevent additive hypoglycemia risk. 1, 2

---

For Fasting Glucose 100–125 mg/dL (Prediabetes/Early Diabetes)

This range indicates impaired fasting glucose requiring intervention to prevent progression to overt diabetes. 1, 3

Lifestyle Intervention (First-Line)

• Weight reduction: 5–10% weight loss contributes meaningfully to improved glucose control. 1
• Physical activity: At least 150 minutes/week of moderate-intensity exercise (aerobic, resistance, flexibility training). 1
• Dietary modification: High-fiber foods (vegetables, fruits, whole grains, legumes), low-fat dairy, fresh fish; limit high-energy foods rich in saturated fats and sweet desserts. 1

Pharmacotherapy Initiation

• If HbA1c <7.5%: Give 3–6 month trial of lifestyle changes before starting medication. 1
• If HbA1c ≥7.5%: Start metformin immediately at diagnosis alongside lifestyle changes. 1
• Metformin dosing: Begin 500 mg once or twice daily with gradual titration to minimize gastrointestinal side effects; target dose 1,000 mg twice daily (2,000 mg total). 1, 2

---

For Random Glucose 140–250 mg/dL

This range indicates inadequate glycemic control requiring medication adjustment or initiation. 1

If Not on Medication

• Start metformin 500–1,000 mg daily, titrate to 1,000 mg twice daily over 2–4 weeks. 1
• Monitor fasting glucose daily during titration; target fasting glucose 80–130 mg/dL. 1, 2

If Already on Metformin Monotherapy

• Add basal insulin if fasting glucose persistently ≥180 mg/dL despite maximum metformin dose. 1, 2
• Starting dose: 10 units once daily at bedtime (or 0.1–0.2 units/kg/day). 1, 2
• Titration: Increase by 2 units every 3 days if fasting glucose 140–179 mg/dL; increase by 4 units every 3 days if fasting glucose ≥180 mg/dL. 2

Alternative Second-Line Options

• GLP-1 receptor agonist (e.g., semaglutide, liraglutide): Provides cardiovascular and renal benefits with weight loss; particularly beneficial if cardiovascular disease, heart failure, or chronic kidney disease present. 2
• SGLT2 inhibitor (e.g., empagliflozin, canagliflozin): Lowers HbA1c by 0.5–0.7% with cardiovascular/renal protection. 2
• DPP-4 inhibitor (e.g., sitagliptin): Adds 0.5–0.8% HbA1c reduction when combined with metformin. 2

---

Critical Threshold: Recognizing "Over-Basalization"

When basal insulin exceeds 0.5 units/kg/day (approximately 35–40 units for most adults) without achieving glycemic targets, stop further basal escalation and add prandial insulin or GLP-1 receptor agonist. 1, 2

Clinical Signs of Over-Basalization

• Basal insulin dose >0.5 units/kg/day without meeting HbA1c goal. 2
• Bedtime-to-morning glucose differential ≥50 mg/dL (indicating excessive overnight basal insulin). 2
• Episodes of hypoglycemia despite overall hyperglycemia. 2
• High day-to-day glucose variability. 2

Adding Prandial Insulin

• Start with 4 units of rapid-acting insulin before the largest meal, or use 10% of current basal dose. 2
• Administer 0–15 minutes before meals for optimal postprandial control. 2
• Titrate by 1–2 units every 3 days based on 2-hour postprandial glucose readings. 2

---

Monitoring Requirements

During Active Titration

• Daily fasting glucose to guide basal insulin adjustments. 1, 2
• Pre-meal glucose before each meal to calculate correction doses. 2
• 2-hour postprandial glucose after meals to assess prandial insulin adequacy. 2
• HbA1c every 3 months during intensive titration. 2

Glucose Targets

• Fasting/pre-meal: 80–130 mg/dL (4.4–7.2 mmol/L). 1
• Postprandial: <180 mg/dL (10 mmol/L). 1
• HbA1c: <7.0% for most adults; individualize based on age, comorbidities, life expectancy. 1

---

Hypoglycemia Management

Treat any glucose <70 mg/dL immediately with 15 grams of fast-acting carbohydrate (4 glucose tablets or 4 oz juice), recheck in 15 minutes, and repeat if needed. 1, 2

• If hypoglycemia occurs without obvious cause: Reduce the implicated insulin dose by 10–20% immediately before the next administration. 1, 2
• Never use rapid-acting insulin at bedtime as a sole correction dose; this markedly raises nocturnal hypoglycemia risk. 2

---

Common Pitfalls to Avoid

• Do not delay insulin initiation when fasting glucose consistently exceeds 180 mg/dL on oral agents; prolonged hyperglycemia increases complication risk. 1, 2
• Never discontinue metformin when starting insulin unless contraindicated; this leads to higher insulin requirements and greater weight gain. 1, 2
• Do not use sliding-scale insulin as monotherapy; major diabetes guidelines condemn this reactive approach as ineffective and unsafe. 1, 2, 4
• Avoid continuing basal insulin escalation beyond 0.5–1.0 units/kg/day without addressing postprandial hyperglycemia; this causes over-basalization with increased hypoglycemia risk. 1, 2
• Do not rely solely on correction doses without adjusting scheduled basal and prandial insulin; this perpetuates inadequate control. 2, 4

---

Expected Clinical Outcomes

• With basal-bolus therapy: Approximately 68% of patients achieve mean glucose <140 mg/dL versus 38% with sliding-scale insulin alone. 2, 4
• HbA1c reduction: 1.5–2.0% with basal insulin optimization alone; additional 2–3% reduction when prandial insulin added. 2
• Properly implemented regimens do not increase hypoglycemia incidence compared with inadequate approaches. 2, 4

---

Special Considerations

Hospitalized Patients (Non-Critical Care)

• Target glucose range: 140–180 mg/dL for most non-critically ill patients. 1, 4
• Insulin therapy initiation threshold: Persistent hyperglycemia ≥180 mg/dL (checked on two occasions). 1
• Basal-bolus regimen: Total 0.3–0.5 units/kg/day (50% basal, 50% prandial) for patients eating regular meals. 1, 2
• High-risk patients (age >65, renal impairment, poor oral intake): Start with 0.1–0.25 units/kg/day. 1, 2

Critically Ill Patients

• Initiate insulin therapy when glucose persistently exceeds 180 mg/dL. 1
• Target range: 140–180 mg/dL for majority of critically ill patients. 1
• Use continuous IV insulin infusion with validated protocols allowing predefined adjustments. 1, 2